Burgdorf, Switzerland-based Ypsomed designed YpsoDose for the subcutaneous self-injection of large-volume doses. ten23 health, a Swiss CDMO, offers drug development, filling and device assembly expertise to contribute to the product offering.
The strategic collaboration sees both parties proactively invest in technology and infrastructure. They want to offer YpsoDose as a fully integrated patch injector. YpsoDose includes a ready-to-use cartriQ glass cartridge from Schott Pharma as the primary packaging, Ypsomed’s patch injector technology and process development, filling, assembly and testing of the final product by ten23 health.
As a result, pharmaceutical customers can receive a rigorously tested and documented overall solution. This accelerates the time to clinic and time to market. The companies say the collaboration harnesses ten23 health’s expertise in developing, manufacturing and testing complex formulations. It also leverages the company’s experience in clinical and commercial fill/finish processes.
The Ypsomed platform gives customers “considerable freedom” in the cohice of components and partners, the company said. Its integrated solution leverages knowledge and allows for collaboration throughout all necessary steps and components.
“Together with ten23 as strong partner, we offer a comprehensive solution, for our customers to bring their medicines to market as a commercially viable and competitive product in a short time, at a lower cost and with low risks,” said Reto Jost, category lead for large-volume injectors at Ypsomed.
